Is dosage reduction appropriate in patients who respond well to anti-TNF-alpha agents?
Jean-Marie
JM
Berthelot
Stéphane
S
Varin
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D012216:Rheumatic Diseases / Q000628:therapy*; D025241:Spondylarthritis / Q000628:therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha